UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 6, 2017
CIDARA THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware
001-36912
46-1537286
(State of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)

6310 Nancy Ridge Drive, Suite 101
San Diego, California 92121
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: (858) 752-6170

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





        


Item 7.01     Regulation FD Disclosure
On April 6, 2017, the slide presentation attached as Exhibit 99.1 was presented in an investor meeting by the management of Cidara Therapeutics, Inc. (the “Company”). Information from this slide presentation may also be used by the management of the Company in future meetings regarding the Company.
The information contained in this Item 7.01 and in Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01.
Financial Statements and Exhibits
(d)  Exhibits .
Exhibit No .     Description
99.1        Slide Presentation, dated April 6, 2017.
        
    






1



SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 6, 2017
CIDARA THERAPEUTICS, INC.
 
By: /s/ Jeffrey Stein, Ph.D.     
Name: Jeffrey Stein, Ph.D.      
Title: President and Chief Executive Officer    


2



EXHIBIT INDEX
Exhibit No.
 
Description
99.1
 
Slide Presentation, dated April 6, 2017.




3
Cidara Therapeutics (NASDAQ:CDTX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Cidara Therapeutics Charts.
Cidara Therapeutics (NASDAQ:CDTX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Cidara Therapeutics Charts.